Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Core Viewpoint - Eyenovia, Inc. is focused on completing the development of its Gen-2 user-filled Optejet device by the third quarter of 2025 while aiming to reduce spending by over 60% [1] Strategic Alternatives - The company has engaged Chardan as its financial advisor to evaluate a range of strategic alternatives, including business combinations, sales, reverse mergers, asset sales, or a combination of these options [1][2] - Eyenovia has not set a timetable for the conclusion of its strategic review and has not made any decisions regarding specific alternatives at this time [3] Product Development - Eyenovia continues to progress the development of its Optejet device, exploring its use as both a consumer user-filled product and a proprietary drug-device combination [2] - The user-filled product could advance through a regulatory pathway without the need for clinical trials and may be commercially available by the end of this year [2] Company Overview - Eyenovia, Inc. specializes in developing its proprietary Optejet topical ophthalmic medication dispensing platform, which is designed to improve treatment options for chronic front-of-the-eye diseases [5]